US Biotech Commission Staff Paper Warns China Is Pulling Ahead on Brain-Computer Interfaces
Summary
Staff of the National Security Commission on Emerging Biotechnology have published a paper arguing that China's coordinated push on brain-computer interfaces is a strategic risk for the United States. It notes that China approved an implantable BCI for commercial use in March 2026, while the US has no national BCI strategy and no commercially available implant. The paper points to a drop of about half in NIH BRAIN Initiative funding over three years, slow FDA review of high-risk devices, and no Medicare coverage pathway. Its recommendations include a national biotechnology coordination office, centralized ethics review for multi-site BCI trials, more transparency on FDA submission deficiencies, and adding BCIs to the RAPID coverage program. The paper says it does not necessarily reflect the Commission's official positions.
Why it matters
It frames BCIs as a US-China competitiveness issue, which could shape US funding, FDA process and reimbursement discussions that affect implant developers. It is a staff white paper, and its funding and timeline figures are its own.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items โ updated daily.
Start free trial